Wednesday, December 07, 2016 9:30:59 AM
I believe that CTCA www.cancercenter.com/ has taken possession of all the goods and the AVAX patents.
Perhaps CTCA might be interested to go on Nasdaq, using shares of AVAX ...
---------------------------------------------
What do you think about: no progression study of O-vax and restarted study about M-vax?
Estimated Enrollment: 387
Study Start Date: July 2016
Estimated Study Completion Date: January 2021
Estimated Primary Completion Date: January 2019 (Final data collection date for primary outcome measure)
https://clinicaltrials.gov/ct2/show/NCT00477906?term=avax&rank=1
Unfortunately: This study is not yet open for participant recruitment
I sent an email to Dr. Henry but without reply...
CONTACTS:
Contact: Henry E Schea 215 241-9760 ext 1302 henry@avax-tech.com
.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM